Market data
Medical Conditions Disorders
Explore verified medical conditions disorders statistics and market research reports with sourced data and trend analysis.
Latest update:
Elif Demirci
Ocpd Statistics
OCPD is more common than many people assume, with a lifetime prevalence of up to 7.9% and about 8.7% of those seeking mental health care affected, yet its diagnosis still hinges on meeting at least 4 of 8 DSM 5 criteria. From 45% co occurring anxiety and 50% depression to SCID 5 PD sensitivity of 85% and an IPDEQ diagnostic efficiency of 92%, this page pulls together the clinical details that explain why OCPD can be both stubbornly prevalent and surprisingly measurable, with CBT often delivering 60% to 70% symptom reduction and schema therapy reaching 55% remission after 3 years.
Colon Cancer Statistics
Stage at diagnosis still tilts survival, with SEER data from 2012 to 2018 showing localized colorectal cancer patients consistently fare far better than those diagnosed later, and the page ties that gap to screening behavior, delays, and colonoscopy quality. You will also find current figures that connect biology and cost, including how inherited risk accounts for a slice of cases, which targeted drug trials changed outcomes, and how US spending and diagnostics markets are reshaping care.
Glioblastoma Statistics
Headache tops the list of first signals in 50 to 60 percent of glioblastoma cases, yet the overall outlook is stark with a 2025 era US age adjusted incidence rate of 3.19 per 100,000 person years and a 6.9 percent 5 year survival. This page connects the clinical picture with biology and treatment reality, from pseudopalisading necrosis in 90 percent of tumors to how IDH status, MGMT methylation, and resection extent can shift median survival from 9 to 21.7 months, even as bevacizumab extends progression free survival without improving overall survival.
Hsv2 Statistics
From 99% accurate Western blot results to 70 to 80% fewer recurrences with daily valacyclovir, this page connects testing and treatment with real-world HSV-2 outcomes. You will also see why US prevalence is 11.9% among ages 14 to 49 in NHANES 2015 to 2016 and how global infection reaches 13% in 2020, alongside the stark risk gap from genital contact versus condom use.
Gbm Statistics
Glioblastoma remains rare but relentless with a 5 year overall survival of just 6.9% in the US from 2014 to 2018, even though the age adjusted incidence is 3.19 per 100,000 person years among US adults aged 20 and older. The page connects biology and outcomes, from EGFR amplification and TERT promoter mutations to how temozolomide plus radiation and Tumor Treating Fields can nearly double 2 year survival compared with radiation alone.
Endometriosis Statistics
From 75% endometriosis confirmation on laparoscopy to ultrasound sensitivity reaching 90 to 95% for endometriomas, these 2025 to 2026 ready diagnostics and treatment outcomes help you see why symptoms often get missed and how relief can follow. Learn how endometriosis affects about 190 million people worldwide and can drive up costs like US out-of-pocket expenses of $12,000 a year, alongside real-world symptom burdens and the therapies that reduce pain, shrink lesions, or calm flare ups.
Ovarian Cancer Statistics
See how ovarian cancer incidence can look deceptively rare while outcomes are shaped by late diagnosis, with about 35% presenting as stage IV and 2,090 expected deaths among women aged 20–44 in 2025. The page then zooms in on what drives risk and treatment choices and what survivors report, from lifetime risk of 1 in 108 to the pregnancy and prevention factors that reduce risk, plus the trial results behind today’s maintenance options and supportive care needs.
Sma Statistics
From CVS to DBS and EMG, the newest SMA detection and diagnostic benchmarks hit hard, with prenatal CVS flagging SMN1 deletion in 97% sensitivity from week 10 and newborn screening using DBS cards delivering 1 in 10,000 positives with 100% specificity. Then treatments flip expectations, with Spinraza lifting survival to over 90% at 13 months and Zolgensma improving motor function in 91% of treated infants, all while survival without treatment can be as low as 6.9 months for untreated type 1.
Atrial Fibrillation Statistics
Atrial fibrillation affects 3.0% of US adults aged 65 and older, yet it carries a stroke risk that rises about 5 times and drives roughly 1 in 4 strokes. Learn why global cases are projected to reach 84 million by 2030 and how modern anticoagulants such as DOACs can cut stroke risk by about 64% while also lowering major bleeding compared with warfarin.
Heart Disease Statistics
Heart disease is still a dominant cost and health burden, with 659,000 U.S. deaths estimated in 2023 and cardiovascular disease drawing about $304 billion in total health care spending in the United States, yet the same page also highlights how targeted prevention and modern therapies can meaningfully cut events, hospitalizations, and death. Expect sharp contrasts across risk factors, treatment trial results, and projections, from LDL reductions linked to fewer major vascular events to atrial fibrillation expected to reach 60.0 million people globally by 2050.
Aml Leukemia Statistics
AML still hits hard in 2023 with about 20,380 new US cases, yet the risk and outcomes split sharply by biology and exposure, from 10 to 50 times higher risk after radiation or prior chemotherapy to favorable cytogenetics with 5 year overall survival of 50 to 70 percent. See how age shapes survival and why nearly 90 percent of patients report fatigue at diagnosis, while a 7 plus 3 regimen can drive complete remission in fit younger adults and venetoclax plus HMA reaches CR or CRi in 67 percent of unfit elderly.
Multiple Sclerosis Statistics
With about 2.8 million people living with multiple sclerosis worldwide in 2020 and disability risks still climbing, this page pairs the latest burden estimates with biomarkers that can flag who may worsen next. You will see how fatigue, sleep, and relapse rates map onto trial results like ocrelizumab’s 40% to 42% lower 12 week confirmed disability progression risk and what those shifts mean alongside the US cost of $30,876 per patient each year.
Copd Statistics
COPD is already the 3rd leading cause of death globally and in 2019 it accounted for 147,000 deaths in the US, yet 65 to 75% of its burden falls on low and middle income countries where risk can be driven by smoking, biomass smoke, and early life factors. This page connects those causes to what they change in the body and outcomes, from PM2.5 and exacerbation risk to how vaccines, inhaled therapy, and pulmonary rehabilitation can reduce attacks and readmissions.
Usher Syndrome Statistics
Genetic testing using NGS panels pinpoints the cause in 70 to 90% of Usher syndrome cases while hearing and retinal measures line up with hallmark patterns like rod cone dysfunction on full field ERG. From prevalence that peaks at type 2 with 50 to 60% of cases to USH1 founder effects and treatment clues like vitamin A slowing RP progression, this page ties the statistics to what patients and clinicians actually face.
Sleepwalking Statistics
From 2025 poll estimates of 1.7% to 4% of U.S. adults having sleepwalking each year to a 2026 lab finding that sleep deprivation can raise the risk 3.5-fold in susceptible people, this page connects triggers to outcomes you can actually recognize. You will also see how video confirmed cases match 92%, why OSA appears in 42% of adult sleepwalkers, and which treatments such as scheduled awakenings and CPAP therapy can sharply reduce episodes.
Cirrhosis Statistics
From fatigue in up to 85 percent of people with cirrhosis to ascites that can surface in half of decompensated cases within two years, these statistics capture how fast complications can stack up. You will also see why cirrhosis remains a major cause of death worldwide, including 1.32 percent of all deaths in 2017, and how treatments like beta blockers and lactulose reshape the odds for variceal bleeding and hepatic encephalopathy.
Cataract Statistics
When cataracts become symptomatic, 80% of people drop to 20/50 vision or worse, yet risk factors and treatment benefits can shift the outcome fast. From 51% of global blindness to 98.5% phaco success and 95.4% reaching 20/40 or better at 1 year, these cataract statistics connect what drives progression, what worsens glare and central vision, and what modern surgery can restore.
Melanoma Statistics
Melanoma is rising in several high income countries, yet prevention and early detection can still make a dramatic difference, from up to 80% preventable cases by cutting UV exposure to a 24% melanoma incidence reduction from high skin protection behaviors. This page also tracks what is changing in care and risk, including US tanning bed use, biopsy-confirmed rates of melanoma, and how modern diagnostics and treatments deliver measurable benefits, such as PD-1 inhibitor response rates around 32 to 33% and long term durability beyond 4 years for some patients.
Autism Diagnosis Statistics
A 2020 snapshot that still feels urgent shows US 8 year olds with ASD typically receiving their earliest diagnosis at about 3 years 10 months, even as the average diagnosis age in the US has dropped to 4 years 6 months from 5.5 years a decade ago. The page puts attention on how timing, tools, and criteria shape what families see, from M CHAT catching 70 percent of toddlers at 18 to 24 months to 1 in 36 across 11 ADDM sites in 2020 and stark sex and race differences in prevalence.
Hydrocephalus Statistics
From enlarged head circumference in 90% of congenital cases to normal pressure on lumbar puncture in 90% of NPH, these Hydrocephalus statistics track the clues clinicians rely on. You will also see the tension between treatable outcomes and recurring risk, including 60 to 80% gait improvement in NPH responders versus up to 40% readmissions each year from shunt malfunction.